This ACOG Committee Opinion, published in February 2020, details the organization’s standpoint on telehealth options including technologically-based services, such as virtual visits or mobile applications. When well-integrated, these services have been shown to be comparable with in-person care, and providers are urged to integrate telehealth into their practices in the appropriate setting. Providers should be well-informed regarding liability, coverage, and state-specific laws with regard to telehealth, and the same level of care should be given to all patients as if they were seen in person. Billing and payment models, which were originally created for in-person services, are still being updated. The Committee Opinion also provides a framework for telehealth in the context of equipment use, medical records, insurance, and medical board requirements.
The availability and high effectiveness of mifepristone/misoprostol regimens for medication abortion have improved access to safe abortion in the first trimester. In this Cochrane review, the authors investigate the safety of patient-administered medication abortion compared to provider-administered. They identified 18 high-quality studies, comprising more than 11,000 women in 10 countries. Most study designs had patients take the mifepristone in the presence of a provider, with misoprostol self-administered at home. The authors found that self-administering the second stage of early medical abortion procedures is as effective as provider-administered procedures for abortion success but found insufficient evidence to compare safety. Further research is needed to determine the effectiveness and safety of self-administration of the entirety of the medication abortion, including mifepristone administration. However, providers can confidently counsel patients that taking their misoprostol at home does not affect the likelihood of a successful medication abortion.
3. Patient Decision Aids to Facilitate Shared Decision Making in Obstetrics and Gynecology (meta-analysis)
In shared decision making providers and patients discuss treatment choices and make a decision together with a shared understanding of the patient’s life situation and priorities. A variety of patient decision aids, from mobile apps to pamphlets, exist to facilitate shared decision making. Researchers performed a systematic review and meta-analysis to assess the utility of these aids in the shared decision making process in obstetrics and gynecology. They found moderate to high evidence to support the use of patient decision aids in the context of shared decision making, but further research is needed to better understand potential costs and the use of appointment time. Overall, this study encourages the use of patient decision aids in shared decision making in obstetrics and gynecology care.
The primary care setting is an important site for increasing access to reproductive health care services such as contraceptive counseling, pre-conception care, and basic infertility care. Accessing these services as well as referrals to the full spectrum of reproductive care within primary care settings may become increasingly important as state and federal regulations limit access to these services. For this study, researchers surveyed patients from a variety of settings in New York State through focus groups and in-depth interviews on their thoughts about exploring reproductive health-related topics in the primary care setting. Overall patients were open to discussions about reproductive health and desired care that utilized a model of shared decision-making. These findings support integration of reproductive health care into the primary care setting and should encourage providers to include these topics in their counseling and care.
5. The Concentration of Fetal Red Blood Cells in First-trimester Pregnant Women Undergoing Uterine Aspiration is Below the Calculated Threshold for Rh Sensitization
Traditionally, Rh-immunoglobulin (Rhogam) prophylaxis is given to all Rh-negative women who experience bleeding during the first trimester, through abortion, miscarriage, or for other reasons. This is done to avoid Rh sensitization which can lead to complications in subsequent pregnancies. However, this prophylaxis can place a large burden on providers and patients, and there is limited data describing lowest thresholds for this intervention. For this study, researchers calculated a threshold of fetal RBCs needed for Rh sensitization based on existing data. Then, they performed flow cytometry on blood samples of women undergoing uterine aspiration for induced or spontaneous abortion at 5-12 weeks gestational age. Although fetal cells were noted in maternal blood samples for all patients, they were consistently well below the estimated threshold for sensitization, suggesting that patients at these gestational ages may not need prophylaxis. This study provides initial data that, when expanded, could provide information on use of prophylaxis during the first trimester.
6. When Patients Change Their Minds After Starting an Abortion: Guidance From the National Abortion Federation’s Clinical Policies Committee
Anti-choice political messaging often claims that patients change their minds about abortion after the procedure has begun. In reality, this is extremely uncommon, as abortion patients on average feel very sure about their decisions and less than 1% of either first trimester or second trimester patients change their mind mid-procedure. For patients who decide not to take misoprostol after taking the mifepristone to begin a medication abortion, small studies indicate continuing pregnancy rates of 23%. Supplemental progesterone is often touted as a way to reverse the effects of mifepristone, but there is no evidence of effectiveness and one small trial was actually stopped due to higher rates of hemorrhage in the attempted reversal group. For patients who change their minds after laminaria placement in the second trimester, two-thirds later had pregnancy complications. The authors conclude that patients’ autonomy must remain primary in the decision to stop or continue with an abortion procedure and counseling should appropriately reflect the risks and potential complications with pregnancy continuation.
7. Intentionally or Ambivalently Risking a Short Interpregnancy Interval: Reproductive-Readiness Factors in Women's Postpartum Non-Use of Contraception
Research has shown a correlation between short interpregnancy intervals (IPI), often defined as a new birth less than 18-24 months after a previous birth, and poorer maternal and neonatal health outcomes. Much of the research on risk factors for IPI has focused on younger parents with lower socioeconomic resources. However, in investigating state-level survey data, the authors found that “reproductive readiness,” defined as older age, parity of one, married status, and reporting first pregnancy as occurring later than desired, were all associated with non-use of contraception postpartum with the intent of becoming pregnant. While providers should continue to counsel patients about the availability of postpartum contraception during and after pregnancy, they should also recognize that patients starting families later in life may risk short IPIs to achieve their family building goals.
8. Relative Risk of Cervical Neoplasms Among Copper and Levonorgestrel-Releasing Intrauterine System Users
This study evaluated the association between cervical neoplasms and IUDs, comparing levonorgestrel (LNG) and copper devices. Researchers used a large institutional database to evaluate patients with either copper or LNG IUDs to determine the rate of development of biopsy-proven, high-grade cervical neoplasms. Even when controlling for confounding factors, they found that patients with copper IUDs had a lower risk of cervical neoplasms as compared to those with LNG IUDs. They note that further research is needed to clarify this finding, and to evaluate the mechanism of this effect. However, this study provides useful information on positive effects of IUD use that go beyond contraception.